Susquehanna International Group, LLP Outlook Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $11,720 - $35,162	53,276 New	53,276 $20,000
Q2 2023 Aug 11, 2023	SELL	$1.02 - $1.89 $34,858 - $64,590	-34,175 Reduced 38.66%	54,218 $94,000
Q1 2023 May 16, 2023	BUY	$1.0 - $1.35 $66,893 - $90,305	66,893 Added 311.13%	88,393 $96,000
Q4 2022 Feb 14, 2023	SELL	$0.87 - $1.33 $12,531 - $19,157	-14,404 Reduced 40.12%	21,500 $23,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $36,622 - $45,239	35,904 New	35,904 $44,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $16,759 - $37,018	-18,417 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $22,468 - $37,386	18,417 New	18,417 $33,000
Q2 2021 Aug 11, 2021	SELL	$1.78 - $2.76 $295,186 - $457,704	-165,835 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $155,884 - $548,913	165,835 New	165,835 $373,000
Q1 2020 May 15, 2020	SELL	$0.51 - $1.08 $5,965 - $12,632	-11,697 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.53 - $1.59 $2,578 - $7,735	-4,865 Reduced 29.37%	11,697 $7,000
Q3 2019 Nov 14, 2019	BUY	$1.32 - $2.63 $21,861 - $43,558	16,562 New	16,562 $25,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.43B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.